KA
LGND icon

Kaizen Advisory’s Ligand Pharmaceuticals LGND Stock Holding History

Kaizen Advisory’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-11,317
Closed -$1.46M – 593
2018
Q2 		$1.46M Buy
11,317
+8,497
+301% +$948K 0.74% 15
2018
Q1 		$291K Buy
+2,820
New +$279K 0.29% 36

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $5.01B AUM 6.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Kaizen Advisory's LGND Position: Q3 2018 in Review

Kaizen Advisory sold out of Ligand Pharmaceuticals (LGND) in Q3 2018, closing a stake of 11,317 shares — an estimated $1.46M sold.

Kaizen Advisory first reported a position in LGND in Q1 2018 and held it in 2 quarters. The position peaked at $1.46M in Q2 2018. 385 funds tracked by Wall St. Rank hold LGND as of Q3 2018.

  • Kaizen Advisory reported no remaining Ligand Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Kaizen Advisory sold 11,317 Ligand Pharmaceuticals shares in Q3 2018, an estimated $1.46M.
  • Kaizen Advisory first reported a position in Ligand Pharmaceuticals in Q1 2018 and held it in 2 quarters.
  • Kaizen Advisory's Ligand Pharmaceuticals position peaked at $1.46M in Q2 2018.
  • 385 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2018.

Based on Kaizen Advisory's 13F filing for Q3 2018, filed 1 Nov 2018.